

## References

### M-7

1. US Food and Drug Administration. 510(k) Premarket Notification. US Department of Health and Human Services website. Accessed December 15, 2021.
2. Verrecchia L, Brantberg K, Tawfique Z, et al. Diagnostic accuracy of ocular vestibular evoked myogenic potentials for superior canal dehiscence syndrome in a large cohort of dizzy patients. *Ear Hear*. 2019; 40(2): 287-294.
3. American Academy of Audiology. Position statement on the audiologist's role in the diagnosis & treatment of vestibular disorders. n.d.; <https://www.audiology.org/publicationsresources/document-library/position-statement-audiologists-role-diagnosis-treatment>. Accessed December 15, 2021.
4. John S, Dechamma S. An electronystagmographic study in post head injury vertigo patients. *Indian J Otolaryngol*. 2020;26(1):27-31.
5. Zhou, H., Sun, Y., Wei, L., et. al. Quantitative assessment of oculomotor function by videonystagmography in multiple system atrophy. *Clinical Neurophysiol*. 2022;141:15-23.
6. Maheu M, Elblidi A, Saliba I. Investigating performance of cVEMP and oVEMP in the identification of superior canal dehiscence in relation to dehiscence location and size. *Audiol Res*. 2021; 11(3):452-462.
7. Lin, Kenny, Lahey et al. Validating the utility of high frequency ocular vestibular evoked myogenic potential testing in the diagnosis of superior semicircular canal dehiscence. *Otol Neurotol* 2109: 40(10):1353-1358.
8. Gedik-Soyuyuce, Ozlem, et al. Vestibular disorders in children: A retrospective analysis of vestibular function test findings. *Int J Pediatr Otorhinolaryngol* . 2021:146; 110751.